Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $9.6 million.

  • Day One Biopharmaceuticals' Share-based Compensation fell 1724.94% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.4 million, marking a year-over-year decrease of 766.88%. This contributed to the annual value of $48.3 million for FY2024, which is 2267.86% up from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Share-based Compensation of $9.6 million as of Q3 2025, which was down 1724.94% from $10.9 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Share-based Compensation ranged from a high of $13.0 million in Q2 2024 and a low of $5.6 million during Q2 2022
  • Over the past 4 years, Day One Biopharmaceuticals' median Share-based Compensation value was $9.6 million (recorded in 2023), while the average stood at $9.9 million.
  • Per our database at Business Quant, Day One Biopharmaceuticals' Share-based Compensation soared by 6830.05% in 2023 and then crashed by 1724.94% in 2025.
  • Day One Biopharmaceuticals' Share-based Compensation (Quarter) stood at $6.8 million in 2022, then surged by 58.22% to $10.8 million in 2023, then grew by 2.07% to $11.0 million in 2024, then decreased by 13.36% to $9.6 million in 2025.
  • Its Share-based Compensation was $9.6 million in Q3 2025, compared to $10.9 million in Q2 2025 and $12.9 million in Q1 2025.